Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Quick MRI may outshine ultrasound for liver cancer detection

NCT ID NCT04288323

Diagnosis Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a shorter, contrast-enhanced MRI (called AMRI) is better than standard ultrasound for finding liver cancer early in people with cirrhosis. 79 adults with cirrhosis underwent both scans, and researchers compared how accurately each method detected cancer. The goal is to improve screening and catch liver cancer sooner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

79 people

The number who actually took part.

Started

Apr 2018

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject has been fully informed and has personally signed and dated the written Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) documents. * Adult subjects of any gender and any ethnic group with liver cirrhosis of any etiology, * Subject is able and willing to complete required research procedures (screening/enrollment, clinical evaluation, safety procedures, lab collection if needed, research AMRI exam, research US exam) and the three optional surveys (if subject opts in for that) within specified time windows, and is willing to allow the study team to review clinical data including but not limited to other clinical radiology reports and images. Exclusion Criteria: * VA patient * \< 18 years of age * History of any liver cancer * MRI contraindication(s) * Subject knows that she is pregnant or states she trying to become pregnant * Positive urine pregnancy test in woman of childbearing potential * Nursing mother * Subject has known allergy to any gadolinium agent * Does not meet UC San Diego Intravenous Contrast Media Guidelines for administration of Eovist\* * Clinical screening exam of the liver performed at UCSD within the prior 90 days to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinoma of liver and intrahepatic biliary tract cirrhosis of liver liver cancer Liver Neoplasms hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cancer Liver carcinoma Liver cirrhoses

Contacts and locations

Locations

  • University of California, San Diego

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.